Novogene Co. Ltd.
Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/IT… Read more
Novogene Co. Ltd. (688315) - Total Assets
Latest total assets as of September 2025: CN¥3.71 Billion CNY
Based on the latest financial reports, Novogene Co. Ltd. (688315) holds total assets worth CN¥3.71 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Novogene Co. Ltd. - Total Assets Trend (2015–2024)
This chart illustrates how Novogene Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Novogene Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Novogene Co. Ltd.'s total assets of CN¥3.71 Billion consist of 69.8% current assets and 30.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.7% |
| Accounts Receivable | CN¥610.48 Million | 16.8% |
| Inventory | CN¥163.72 Million | 4.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥41.65 Million | 1.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Novogene Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novogene Co. Ltd.'s current assets represent 69.8% of total assets in 2024, a decrease from 82.9% in 2015.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2024, down from 17.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 16.8% of total assets.
Novogene Co. Ltd. Competitors by Total Assets
Key competitors of Novogene Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Novogene Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Novogene Co. Ltd. generates 0.58x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Novogene Co. Ltd. generates $5.41 in net profit.
Novogene Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.61 | 2.38 | 1.34 |
| Quick Ratio | 2.35 | 2.20 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.67 Billion | CN¥ 1.39 Billion | CN¥ 304.39 Million |
Novogene Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Novogene Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.45 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | CN¥3.64 Billion |
| Market Capitalization | $259.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Novogene Co. Ltd.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Novogene Co. Ltd.'s assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Novogene Co. Ltd. (2015–2024)
The table below shows the annual total assets of Novogene Co. Ltd. from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.64 Billion | +1.18% |
| 2023-12-31 | CN¥3.59 Billion | +17.92% |
| 2022-12-31 | CN¥3.05 Billion | +6.61% |
| 2021-12-31 | CN¥2.86 Billion | +41.22% |
| 2020-12-31 | CN¥2.02 Billion | +2.77% |
| 2019-12-31 | CN¥1.97 Billion | +33.90% |
| 2018-12-31 | CN¥1.47 Billion | +8.78% |
| 2017-12-31 | CN¥1.35 Billion | +10.23% |
| 2016-12-31 | CN¥1.23 Billion | +155.59% |
| 2015-12-31 | CN¥480.08 Million | -- |